Johnson & Johnson

- On page 7, there is no explicit mention of any current or future new fundraising through debt or equity. - The transcript focuses on product developments, business growth, and operational performance. - Financial discussions on page 5 and 4 include earnings, sales, and margin projections but do not detail plans for new fundraising. - The emphasis is on organic growth, acquisitions, and capital allocation priorities managed through free cash flow. - Joaquin Duato and other executives highlight confidence in innovation and pipeline to drive growth without indicating new fundraises.

- Increased capital investment in the U.S. was highlighted as a factor impacting free cash flow in 2025. - The company plans to invest the majority of operating efficiencies in 2026 into the business to power new product launches and pipeline expansion. - Progress is being made towards a mid-2027 orthopedic separation, indicating a significant strategic investment. - Expansion plans include advancing the Otava robotic surgical system and other new products in medtech. - Continued investment in manufacturing footprint improvements to enhance gross margin. - Pruning of portfolio with focus on high growth markets; aiming for over 70% of assets in markets growing above 5% post orthopedic separation. - Commitment to launch additional catheters each year in electrophysiology. - Capital allocation aims to sustain double-digit revenue growth and accelerate operational growth through innovation and commercial execution.

- Johnson & Johnson anticipates 2026 operational sales growth of 5.7% to 6.7%, with a midpoint of 6.2% (~$100 billion), and reported sales growth between 6.2% to 7.2%. - Adjusted operational sales growth midpoint is 5.9%, benefiting from acquisitions and favorable currency impacts. - The company expects to accelerate top-line growth over the next several years, targeting double-digit growth by the end of the decade. - Sales growth drivers include continued uptake and market expansion of new product launches across cardiovascular, surgery, vision, and innovative medicines (e.g., RZALEX, CARVICTI, ERLEADA). - MedTech sales projected to grow via new product launches (e.g., VariPulse, Oasis Max lenses, Optava robotic surgical system). - Innovative Medicines anticipate regulatory approvals and launches in oncology, immunology, and neuroscience to contribute to growth. - Volume-based procurement in China and accelerated transformation in surgery expected to support MedTech growth. - Overall, consistent margin expansion of at least 50 basis points in 2026, aligned with sales growth.

- Johnson & Johnson anticipates adjusted operational sales growth of 5.7% to 6.7% in 2026, with a midpoint of 6.2%, and reported sales growth of 6.2% to 7.2%. - Adjusted pretax operating margin is expected to improve by at least 50 basis points in 2026 despite increased investments and tariffs. - Net interest expense is projected between $300 million and $400 million; net other income forecasted at $1 to $1.2 billion, flat to 2025. - Adjusted operational earnings per share (EPS) guidance is $11.28 to $11.48 with a midpoint growth of 5.5%. Reported adjusted EPS is expected at $11.53 midpoint. - Earnings per share growth is projected to be higher in the second half of 2026 due to factors including the 53rd week of operations and tariff impacts. - Free cash flow is expected to elevate to approximately $21 billion in 2026, supporting continued business investment and shareholder returns.

The provided pages from the Johnson & Johnson 2025 earnings call transcript do not explicitly mention details about the current or expected orderbook or pending orders. The discussion focuses primarily on: - Strong sales growth across multiple business units (Innovative Medicine, MedTech, etc.). - Robust pipeline with new product launches, approvals, and clinical trials. - Positive momentum in key areas like oncology, immunology, neuroscience, cardiovascular, surgery, and vision. - Growth drivers including new therapies and technologies. - Increased focus on innovation and high-growth segments. - Expected accelerated growth in 2026 and double-digit growth by the end of the decade. Thus, no specific quantitative data or details related to orderbook or pending orders are provided in the selected content.